Saturday 17 October 2026
Export KPRX’s income statement to Excel — free account
Kiora Pharmaceuticals, Inc.
KPRX Healthcare Biotechnology
Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million. In the quarter to June 2026, EPS grew 37.0% and free cash flow grew 50.1%, each against the same quarter a year earlier.
2.40
0.01
−0.41%
Follow KPRX
Kiora Pharmaceuticals, Inc. (KPRX) P/E ratio
Kiora Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.8× (January 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 1.5× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2020 | 0.0× | — |
| Mar 2019 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1.8×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPRX Kiora Pharmaceuticals, Inc. | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| PTN Palatin Technologies, Inc. compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| TPST Tempest Therapeutics, Inc. compare | n/m |
| BLRX BioLineRx Ltd. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)